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Cardiovascular diseases (CVD), including
heart disease and stroke, comprise the
global leading cause of morbidity and mor-
tality collectively killing 12.9 million people
in 2010, or one in four deaths worldwide
(1). In the United States, CVD account
for more than one-third of all deaths, and
~150,000 deaths per year occur in indi-
viduals younger than 65 years (2). Apart
from serious consequences for the diseased
individuals and their families, CVD is also
associated with huge costs for society. It
has been estimated that CVD and related
conditions consume about a third of the
total health care costs in the European
Union (3). In 2010, the total costs of CVDs
in the United States were estimated to be
$444 billion (2). It should be noted that
CVD is by no means an isolated problem
for high-income countries. On the con-
trary, low- and middle-income countries
are disproportionally affected,as more than
80% of all CVD deaths take place in such
countries (4). In fact, many low-income
countries are now facing a “double bur-
den”of disease, where they continue to deal
with the problems of communicable dis-
eases and undernutrition, but at the same
time they are experiencing rapidly increas-
ing incidences of non-communicable dis-
eases, primarily CVD and type 2 diabetes.
Parts of this can be ascribed to an ongo-
ing obesity epidemic, particularly in urban
settings. According to estimations by the
World Health Organization (WHO), more
than 1.4 billion adults were overweight and
more than 10% of the world’s adult pop-
ulation was obese in 2008 (5). It is not
uncommon to find malnutrition and obe-
sity existing side-by-side within the same
country, same community, and even same
household, and global burden from adi-
posity is projected to increase further in
the next decade (5). Other reasons for the
rapidly increasing CVD rates in low- and
middle-income countries include higher
exposure to risk factors, such as tobacco
use, unhealthy diet, and physical inactivity;
and less access to effective and equitable
health care services. These factors lead to
less control of hypertension, diabetes, and
hyperlipidemia, and as a result, higher inci-
dence of CVD. This rapidly increasing inci-
dence of CVD comprises a global major
challenge for public health and medical
care in the decades to come (6).
Major advances in the understanding
of causes and pathophysiology of CVD
were made already during the 1960s and
1970s, and the widely recognized CVD
risk factors, such as smoking, hyperten-
sion, hypercholesterolemia, type 2 diabetes,
obesity, lack of physical activity, and fam-
ily history were established before 1975
(7). In the following decades, as a result
of increased understanding of the patho-
physiology of ischemic heart disease, car-
diac care was radically improved and major
pharmaceutical drugs have contributed to
dramatically decreasing case fatality rates
and improved survival in patients with
myocardial infarction. In contrast, simi-
lar dramatically improved survival rates
have not been observed for stroke or heart
failure – two other major contributors to
CVD deaths. Further, although efforts to
decrease cholesterol levels and smoking
have been successful in the United States
and Europe over the past two decades, we
now see increasing prevalences of obesity
and type 2 diabetes. Worrying observations
include that overweight is being normal-
ized in society (8), and that only ~1% of
individuals in the United States reach what
has been defined as “ideal cardiovascular
health” by the American Heart Association
(9, 10). In addition, the CVD incidence is
now rising rapidly in developing countries
as a result of adaptation to a westernized
lifestyle.
So, it appears that although we know
what is needed in terms of lifestyle changes
to prevent CVD, the successes of imple-
menting these in the general population are
limited. For primary and primordial pre-
vention, it is useful to distinguish between
high-risk and population-wide strategies.
In the former, we aim to identify the indi-
viduals at highest risk of developing disease
and target them with preventive measures.
An example of this is the more or less orga-
nized screening for high blood pressure and
hyperlipidemia with the subsequent treat-
ment to lower CVD risk. Further, much of
the ongoing research focusing on finding
new biomarkers to better stratify individ-
uals into categories of high or low CVD
risk are also aimed at improving the high-
risk prevention strategy. Population-wide
strategies are instead targeting the whole
population to shift the risk factor dis-
tribution. The perhaps most well-known
example of a successful population-wide
prevention program is the North Karelia
Project in Finland, where the decline in
mortality from ischemic heart disease was
twice as large in this region as compared
to the rest of Finland between 1969 and
1979 (24 vs. 12% in men; 51 vs. 24% in
women) (11). However, this and several
other examples of successful prevention
programs in the community notwithstand-
ing, the global trends of increasing burden
from CVD and increasing risk factors give
us a clear signal. New strategies for control
of CVD risk factors and prevention of CVD
in the community are desperately needed,
and this is not only one of the grand chal-
lenges of cardiovascular epidemiology, but
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poses as one of the central threats to global
public health calling for urgent action.
Furthermore, even if there are a few
exceptions like ticagrelor (platelet aggre-
gation inhibitor), rosuvastatin (second-
generation statin), and rivaroxaban (oral
anticoagulant); the pharmaceutical indus-
try at large has been unsuccessful in devel-
oping new drugs for primary and sec-
ondary prevention of CVD in the past
decade. Hence, there is a large need for revi-
talization of the cardiovascular field with:
(a) improved risk prediction and more ade-
quate individually tailored treatment; and
(b) new targets for drug development based
on pathways previously unknown to be
involved in CVD pathophysiology.
Great progress has been made in defin-
ing the genetic architecture of CVD and
associated conditions over the past 5 years
as a result of the development of high-
throughput genotyping technology and its
main application; genome-wide associa-
tion studies (GWAS). This knowledge has
provided many new clues to disease patho-
physiology through implication of biolog-
ical pathways previously not hypothesized
to be involved in the development of dis-
ease. There are already good examples of
how new important biology has been dis-
covered using this technique (12), but the
full impact of GWAS findings is yet to be
explored through follow-up studies. In par-
allel with the rapid development of geno-
typing using microarray techniques and
bioinformatic analyses of single nucleotide
polymorphisms (SNPs) from such plat-
forms, the technological development in
next generation sequencing methods has
been dramatic, by far exceeding Moore’s
law (that predicts a doubling of com-
puting power every 2 years). From Jan-
uary 2008 to the present day, the cost
for a high-coverage whole-genome scan
has decreased from 10 million USD to
1,000 USD – the “1000-dollar genome”
can now be achieved using the Illumina
HiSeq X Ten platform. Sequencing plat-
forms can be used for a range of applica-
tions, including DNA sequencing to map
causal variants and explore rare varia-
tion, RNA sequencing for expression analy-
ses, and methylation sequencing for epi-
genetic studies. Other large-scale omics
techniques that are currently undergoing a
rapid development include proteomics and
metabolomics using mass spectrometry,
nuclear magnetic resonance spectroscopy,
or affinity-based techniques. The full scope
of these methods has still not been appreci-
ated, but with the rapidly decreasing costs
and increasing throughput, we are now
able to start implementing them in large
population-based study samples to disen-
tangle the mechanisms leading to CVD.
Standing at the brink of this omics
revolution, it is quite clear that the oppor-
tunities for exploration of new pathways
leading to CVD and other complex dis-
eases using these methods are previously
unseen, and that the full power will
be reached by combining data from all
of these methods. By studies through
the whole chain of intermediate steps,
DNA→mRNA→ protein→metabolites
→ subclinical CVD→ overt CVD, and
the complex interactions between parts of
these pathways, we can improve under-
standing of CVD pathophysiology to
identify new drug targets, as well as
novel biomarkers for risk stratification
and treatment decisions.
The grand challenge of cardiovascular
epidemiology is to turn the tide of increas-
ing CVD morbidity and mortality glob-
ally. To do this, we will need new tools
for better risk stratification to maximize
efficiency of high-risk strategies for preven-
tion; new approaches to population-wide
prevention; and new knowledge about the
mechanisms leading to CVD to provide
leads for development of a new generation
of pharmaceutical drugs. As the Charles
Dickens novel “A Tale of Two Cities” begins
“It was the best of times, it was the worst of
times, itwas the age of wisdom,”I believe that
cardiovascular epidemiologists are indeed
living in a challenging time with increas-
ing burden from CVD and limited success
in primary prevention, but at the same
time in the best of times with the rapid
developments of new tools for biomed-
ical discoveries. It is the goal of Frontiers
in Cardiovascular Medicine to provide a
forum for presenting creative research and
new approaches to meet the challenges of
our time. We hope that you want to take
us up on the grand challenges of cardio-
vascular epidemiology, and help us turning
the tide.
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